Intelligo

Private limited company · Oslo

XELLIA PHARMACEUTICALS AS

ActiveResearch and experimental development on natural sciences and engineering (72.100)

Founded
16 May 1994
Employees
30
Chief executive
Gael Laurence Bernard
Business address
Silurveien 2, 0380 Oslo

The life line 1997–2026

Operating revenue per year, with recorded events above. As a table

Operating revenue 2025: NOK 75.4m.

  1. Managing director took office§ 07
  2. Chair took office§ 07

Sources: the Register of Company Accounts (company accounts), fetched 15 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.

In brief

XELLIA PHARMACEUTICALS AS is a private limited company in Oslo, founded in 1994, in the industry research and experimental development on natural sciences and engineering. The chief executive is Gael Laurence Bernard, and the chair of the board is Anne Mette Nygård. In 2025 the company had NOK 75.4m in operating revenue and a net profit of NOK −944k. The largest owner is XELLIA GROUP AS with 100.0%.

Put together by Intelligo from the sections below; each figure stands with its source where it belongs.

Overview

§ 01 Latest changes

4 changes, latest 14 Oct 2026

  • Number of employees 29 → 30
  • Endring av daglig leder
  • Annual accounts filed 2024 → 2025
  • Godkjente årsregnskap

Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →

Overview

§ 02 Worth knowing

1 point

  • OKEquity ratio 91.2%, above the industry median

Assumed: derived by Intelligo by fixed rules, not a credit rating. How we calculate

Overview

§ 03 Key figures

Revenue NOK 75.4m in 2025

Revenue

NOK 75.4m

−9.3% from 2024

20232025

Operating profit

NOK 5.7m

−21.2% from 2024

20232025

Net profit

NOK −944k

−101.3% from 2024

20232025

Equity

NOK 672.5m

−4.9% from 2024

20232025

Source: the Register of Company Accounts, read 15 Nov 2026 · The full accounts →

Finances

§ 04 Where the money comes from and goes

Financial year 2025

Of every krone of operating revenue in 2025:

  • Wages and social costs 63%
  • Depreciation 4%
  • Other operating costs 24%
  • Left as operating result 8%

Source: the Register of Company Accounts via areg.no, read 15 Nov 2026

Finances

§ 05 Financial health

Equity ratio 91.2%

RevenueNOK 75.4m Operating margin7.6% Equity ratio91.2% Revenue growth−9.3%
  • XELLIA PHARMACEUTICALS AS, 2025
  • Industry median, assumed: NOK 1.5m · −4.4% · 48.9% · +3.0%

Equity NOK 672.5m91% of the assets (NOK 737.7m)

Source: the Register of Company Accounts, read 15 Nov 2026. The median is derived by Intelligo from 694 companies in 72.100 Research and experimental development on natural sciences and engineering, not stated by the source.

Finances

§ 06 Accounts

28 years, latest 2025

NOK 1,0002023–25202520242023
Operating revenue75,43583,14585,872
Operating profit5,7467,2906,982
Profit before tax8,59586,23650,609
Net profit−94474,37942,946
Total assets737,714781,317732,234
Equity672,493707,205674,435
Liabilities65,22174,11257,799

Source: the Register of Company Accounts, read 15 Nov 2026 · All 28 years →

Management and ownership

§ 07 Officers

11 officers now

The board: 5 members

Source: the Brønnøysund Register Centre, read 11 Sep 2026 · All 11 roles, former ones too →

Management and ownership

§ 08 Signature, procuration and authorisations

May sign for the company:

Styrets leder og nestleder i fellesskap. Styrets leder eller nestleder sammen med daglig leder. Styrets leder eller nestleder sammen med to styremedlemmer. Daglig leder sammen med to styremedlemmer.

Procuration: none registered.

The signature is word for word from the register. Source: the Register of Business Enterprises, read 23 Aug 2026

Management and ownership

§ 09 Owners

1 shareholder · largest 100.0%

OwnerShare
XELLIA GROUP AS
100.0%

Source: the Tax Administration's Register of Shareholders as of 31 December 2025, read 31 Jul 2026 · All 1 owners →

Management and ownership

§ 10 Group

None registered

Not a group.No subsidiaries in the shareholder register, and no group accounts. Checked 15 Nov 2026.

Management and ownership

§ 11 Portfolio

None registered

No holdings registered.The shareholder register has no shares held by the company. Checked 15 Nov 2026.

Management and ownership

§ 12 Network

4 connections

  • Person
  • Company

2 people link XELLIA PHARMACEUTICALS AS to 2 other companies: Eva Blem 2 and Søren Hostrup 2.

Source: the Brønnøysund Register Centre, read 11 Sep 2026 · Explore the network →

Events and registers

§ 13 Events

14 since 2015

Events per year

20152026

  • Notices19
  • Register changes6

Since 2015: 19 announcements and 6 register changes. Most happened in 2023 and 2026.

Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 16 Nov 2026. Register changes are Intelligo's own observations. · All 14 events →

Events and registers

§ 14 Notices

19, latest 25 Aug 2026

  • Daglig leder
  • Godkjente årsregnskap
  • Styre

Source: The Brønnøysund Register Centre's announcements ↗, read 16 Nov 2026 · All 19 →

Events and registers

§ 15 Charges

Not fetched yet

Events and registers

§ 16 Other registers

Found in 3 of 7

  • The Central Coordinating RegisterRegistered 12 Mar 1995
  • VATRegistered
  • The Register of Business EnterprisesRegistered 28 Sep 1994
  • The Cleaning RegisterNot registered
  • The Register of Staffing AgenciesNot registered
  • Smiley scheme, the Norwegian Food Safety AuthorityNot registered
  • The Financial Supervisory Authority's licence registerNot registered

Purpose: Utvikling, tilberedning og forhandling av farmasøytiske aktivstoffer, ferdig legemidler og dyrehelsepreparater og andre produkter i den utstrekning styret bestemmer, samt deltagelse som aksjonær, lånegiver, garantist eller på annen måte i andre foretagender.

Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026

Market

§ 17 Tenders

None registered

No tenders recorded.No public tenders won, lost or announced, in Doffin or TED. Checked 15 Nov 2026.

Market

§ 18 Vacancies

None registered

No vacancies.No open ads at NAV. Checked 15 Nov 2026.

Market

§ 19 Competitors

Industry code 72.100

The companies most like it:

Compare them

The selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →

Last

§ 20 Questions and answers

7 questions

  • Who is the chief executive of XELLIA PHARMACEUTICALS AS?
    Gael Laurence Bernard, since 2026. § 07
  • Who owns XELLIA PHARMACEUTICALS AS?
    1 shareholder. It is XELLIA GROUP AS with 100.0%. § 09
  • What was the revenue in 2025?
    NOK 75.4m in the company. § 06
  • Who can sign for XELLIA PHARMACEUTICALS AS?
    Styrets leder og nestleder i fellesskap. Styrets leder eller nestleder sammen med daglig leder. Styrets leder eller nestleder sammen med to styremedlemmer. Daglig leder sammen med to styremedlemmer. § 08
  • Who is the auditor?
    PRICEWATERHOUSECOOPERS AS. § 07
  • Where is XELLIA PHARMACEUTICALS AS based?
    Silurveien 2, 0380 Oslo.
  • When was XELLIA PHARMACEUTICALS AS founded?
    16 May 1994, registered in the Register of Business Enterprises 28 Sep 1994. § 16

The answers come from the sections linked to, with their sources.

01Latest changesOverviewContentsClose